Nalidin (Naloxone Hydrochloride, Tilidine Hydrochloride)

Naloxone Hydrochloride, Tilidine Hydrochloride, the active ingredients in Nalidin, are a combination opioid antagonist and pro‑drug analgesic presented as an oral formulation for systemic use. It is employed to reverse opioid overdose effects and to provide analgesia for moderate pain.

GNH USA supplies Nalidin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance support.

Nalidin combines naloxone and tilidine, acting on opioid pathways to address both overdose and pain management.

- Opioid overdose: rapidly reverses respiratory depression, sedation and other life‑threatening effects of opioid toxicity. - Moderate to severe pain: provides analgesia after conversion of tilidine to nortilidine, useful in acute and chronic pain settings. - Post‑operative pain: manages postoperative discomfort when opioid analgesia is required but rapid reversal may be needed.

Nalidin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Dizziness: transient light‑headedness or vertigo. - Sweating: increased perspiration, especially during reversal of opioid effects. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Seizures: convulsive episodes, particularly in patients with predisposition. - Severe hypotension or hypertension: abrupt changes in blood pressure requiring medical attention. - Anaphylactic reaction: life‑threatening allergic response with rash, swelling, and respiratory compromise.

When prescribing Nalidin, consider the following precautions to ensure safe use.

- Assess opioid dependence: evaluate risk of precipitated withdrawal before administration. - Monitor cardiovascular status: watch for hypertension, tachycardia or hypotension during reversal. - Avoid use in known hypersensitivity: contraindicated in patients allergic to naloxone or tilidine. - Use with caution in hepatic impairment: metabolism of tilidine may be altered, requiring close observation. - Pregnancy and lactation: consult specialist before use as safety data are limited. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Nalidin can interact with other medicines; key interactions are categorized by clinical significance.

Major Interactions (Avoid): - Other opioid antagonists: additive antagonism may eliminate needed analgesia. - Central nervous system depressants (e.g., benzodiazepines, alcohol): risk of enhanced respiratory depression when opioid effect is abruptly reversed.

Moderate Interactions (Monitor Closely): - Opioid agonists: may reduce analgesic efficacy; dose adjustments may be required. - MAO inhibitors: can increase risk of hypertensive episodes with tilidine. - Serotonergic agents: potential for serotonin syndrome when combined with tilidine.